In:
Clinical and Molecular Hepatology, The Korean Association for the Study of the Liver, Vol. 27, No. 3 ( 2021-07-01), p. 463-473
Abstract:
Background/Aims: Useful biomarkers for metabolic syndrome have been insufficient. We investigated the performance of serum milk fat globule-EGF factor-8 (MFG-E8), the key mediator of inflammatory pathway, in diagnosis of metabolic syndrome.Methods: Subjects aged between 30 and 64 years were prospectively enrolled in the Seoul Metabolic Syndrome cohort. Serum MFG-E8 levels were measured at baseline.Results: A total of 556 subjects were included, comprising 279 women (50.2%) and 277 men (49.8%). Metabolic syndrome was diagnosed in 236 subjects (42.4%), and the mean MFG-E8 level of subjects with metabolic syndrome was significantly higher than that of subjects without metabolic syndrome (P 〈 0.001). MFG-E8 level was significantly correlated with all metabolic syndrome components and pulse wave velocity (all P 〈 0.05). Subjects were categorized into two groups according to the best MFG-E8 cut-off value as follows: group 1, MFG-E8 level 〈 4,745.1 pg/mL (n=401, 72.1%); and group 2, MFG-E8 level ≥4,745.1 (n=155, 27.9%). At baseline, metabolic syndrome in group 2 was significantly more prevalent than in group 1 (63.9% vs. 34.2%, P 〈 0.001). During median follow-up of 17 months, metabolic syndrome developed in 122 (38.1%) subjects among 320 subjects without it at baseline. The incidence of metabolic syndrome in group 2 was significantly higher than that in group 1 (55.4% vs. 34.5%, P=0.003). On multivariate analysis, MFG-E8 level ≥4,745.1 pg/mL was an independent predictor for diagnosis and development of metabolic syndrome after adjusting other factors (all P 〈 0.05).Conclusions: Serum MFG-E8 level is a potent biomarker for the screening and prediction of metabolic syndrome.
Type of Medium:
Online Resource
ISSN:
2287-2728
,
2287-285X
DOI:
10.3350/cmh.2020.0351
Language:
English
Publisher:
The Korean Association for the Study of the Liver
Publication Date:
2021
detail.hit.zdb_id:
2672531-9
